Inventiva SA :Secures €21.4 Million And Completes The First Tranche Of The Previously Announced Multi-Tranche Financing Of Up To €348 Million.Additional Cash Requirements Estimated At €120 Million To €130 Million.Proceeds To Advance Phase Iii Nativ3 Clinical Trial.Appoints Mark Pruzanski As Chairman And Srinivas Akkaraju To Board.Company Estimates Financing Operations Until Mid-Q3 2025.Net Proceeds Of €20.1 Million To Fund Clinical Program And Corporate Purposes.Board Approves Second Phase Of Tranche 1 For €21.4 Million.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments